PDF herunterladen
Nervenheilkunde 2004; 23(03): 151-159
DOI: 10.1055/s-0038-1626294
Original- und Übersichtsarbeiten - Original and Review Articles
Schattauer GmbH

Arzneimittelinteraktionen bei der Antiparkinson-Therapie

Drug interactions in antiparkinsonian therapy
E. J. Verspohl
1   Abteilung Pharmakologie, Institut für Pharmazeutische und Medizinische Chemie, Münster
,
F. A. Engfer
2   Schering Deutschland GmbH Berlin, Geschäftseinheit Spezial-Therapeutika, Medizin Neurologie
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
19. Januar 2018 (online)

Auch verfügbar auf
    Lizenzen und Reprints

Zusammenfassung

Parkinson-Patienten müssen häufig gleichzeitig mit Medikamenten gegen weitere Erkrankungen behandelt werden. Das Interaktionsrisiko ist dabei hoch und kann lebensbedrohlich sein. Mögliche Interaktionen können häufig auch bei guten pharmakologischen Kenntnissen nicht vorhergesagt werden, sondern müssen in Review-Artikeln oder Datenbanken nachgeschlagen werden. Abgehandelt werden die relevanten Interaktionen aller Antiparkinsonmittel untereinander, ferner solche mit Psychopharmaka, gastrointestinalen Therapeutika, Herz-Kreislauf-Mitteln, Nahrungsbestandteilen, Vitaminen, Eisensalzen, Mitteln bei Blutgerinnungsstörungen, Narkotika und Analgetika. Tabellen helfen bei der Schnellsuche. Wichtige Empfehlungen für den Alltag in Klinik und Praxis werden gegeben, um so die Arzneimittelsicherheit zu erhöhen.

Summary

Patients with parkinson symptoms are often co-medicated with drugs against additional diseases. Combination therapies may induce drug interactions including lifethreatening events. Drug interactions cannot be anticipated on the basis of having a good pharmacological background but have to be confirmed using reviews or data banks. The relevant interactions of all antiparkinsonian drugs with themselves, with psychopharmacological drugs, drugs used for gastrointestinal and cardiology complaints, with food, vitamins and iron salts, with drugs influencing bleeding, with narcotics and analgetics are described and listed. Hints to react on or correct the interactions are given. Thus drug safety would be increased.

Schlüsselwörter

Antiparkinson-Medikamente - Parkinson-Krankheit - Arzneimittelinteraktionen

Keywords

Antiparkinsonian agents - Parkinson’s disease - drug interactions
 

  • Literatur

  • 1 Pfeiffer RE. Antiparkinsonian agents. Drug interactions of clinical significance. Drug Safety 1996; 14: 343-54.
    PubMedSuche in Google Scholar
  • 2 Cluff LE, Petrie JC. Clinical effects of interaction between drugs. Excerpta Medica. Amsterdam. 1974
    PubMedSuche in Google Scholar
  • 3 Kuzuhara S. Drug-induced psychotic symptoms in Parkinson’s disease. Problems, management and dilemma. J Neurol 2001; 248 (Suppl. 03) III 28-31.
    CrossrefPubMedSuche in Google Scholar
  • 4 Hanzal F. Treatment of Parkinson’s syndrome with L-dopa and L-carbidopa. Munch Med Wochenschr 1976; 118: 653-6.
    Suche in Google Scholar
  • 5 Saller R, Berger Th, Ulmer E, Hellenbrecht M. Praktische Pharmakologie. 2nd Edition.. Stuttgart: Schattauer; 1983
    Suche in Google Scholar
  • 6 Schwarz J. Morbus Parkinson. In: Lehmann-Horn F, Ludolph AC. (eds). Neurologische Therapie. München: Urban & Fischer; 2000
    Suche in Google Scholar
  • 7 Skiric P, Geber J, Ivanovic D, Suchanek E, Gjuris V, Tucan-Foretic M, Mise S, Cvitanovic B, Rotkvic I. Dopamine antagonists induce gastric lesions in rats. Eur J Pharmacol 1986; 131: 105-9.
    CrossrefPubMedSuche in Google Scholar
  • 8 Jost WH. Therapie des idiopathischen Parkinson-Syndroms. 2nd.. Bremen: Edition Uni-med Verlag.;
  • 9 Dalvi A, Ford B. Antiparkinsonian Agents. Clinically significant drug interactions and adverse effects, and their management. CNS Drugs 1995; 09: 291-310.
    Suche in Google Scholar
  • 10 Bozek CB, Suchowersky O, Purves S, Calne S, Calne DB. Sinemet in Parkinson’s disease: efficacy with and without food. Clin Neuropharmacol 1986; 09: 196-9.
    CrossrefSuche in Google Scholar
  • 11 Baruzzi A, Contin M, Riva R, Procaccianti G, Albani F, Tonello C, Zoni E, Martinelli P. Influence of meal ingestion time on pharmacokinetics of orally administered levodopa in parkinsonian patients. Clin Neuropharmacol 1987; 10: 527-37.
    CrossrefPubMedSuche in Google Scholar
  • 12 Dingemanse J, Kleinbloesem CH, Crevoisier Ch, Lankhaar G, Gasser UE. Pharmacokinetic studies with a dual-release formulation of Levodopa, a novel principle in the treatment of parkinson’s disease. Eur Neurol 1998; 39: 119-24.
    CrossrefPubMedSuche in Google Scholar
  • 13 Robertson DRC, Higginson I, Macklin BS, Renwick AG, Waller DG, George CF. The influence of protein containing meals on the pharmacokinetics of levodopa in healthy volunteers. Br J Clin Pharmacol 1991; 31: 413-7.
    CrossrefPubMedSuche in Google Scholar
  • 14 Contin M, Riva R, Martinelli P, Albani F, Baruzzi A. Effect of the meal timing on the kinetic-dynamic profile of levodopa/carbidopa controlled is release in parkinsonian patients. Eur J Clin Pharmacol 1998; 54: 303-8.
    CrossrefPubMedSuche in Google Scholar
  • 15 Yeh KC, August TF, Bush DF, Lasseter KC, Musson DG, Schwartz S, Smith ME, Titus DC. Pharmacokinetics and bioavailability of Sinemet CR: A summary of human studies. Neurology 1989; 39 (Suppl. 02) 25-38.
    CrossrefPubMedSuche in Google Scholar
  • 16 Caranasos GJ, Stewart RB. Clinically desirabele drug interactions. Ann Rec Toxicol 1985; 25: 67-95.
    Suche in Google Scholar
  • 17 Camicioli R, Lea E, Nutt JG, Sexton G, Oken BS. Methylphenidate increases the motor effects of L-Dopa in Parkinson`s disease: a pilot study. Clin Pharmacol 2001; 24: 208-13.
    Suche in Google Scholar
  • 18 Senard JM, Brefel-Courbon C, Rascol O, Montastruc JL. Orthostatic hypotension in patients with parkinsons disease: pathophysiology and management. Drugs Aging 2001; 18: 495-505.
    CrossrefPubMedSuche in Google Scholar
  • 19 Quinn N, Illas A, Lhermitte F, Agid Y. Bromocriptine and domperidone in the treatment of Parkinson disease. Neurology 1981; 31: 662-7.
    CrossrefPubMedSuche in Google Scholar
  • 20 Jost WH, Brück C. Drug Interactions in the treatment of Parkinson`s disease. J Neurol. 2002. 249: III 24-29.
    Suche in Google Scholar
  • 21 Kulig K, Moore LL, Kirk M, Smith D, Stallworth J, Rumack B. Bromocriptine-associated headache: possible life-threatening sympathomimetic interaction. Obstet Gynecol 1991; 78: 941-3.
    PubMedSuche in Google Scholar
  • 22 Martignoni E, Pacchetti C, Godi L, Rainer E, Horowski R, Nappi G. Treatment of »de novo« PD patients with lisuride and L-deprenyl combines: A long term study. New Trends Clin Neuropharmacol 1992; 06: 53-7.
    Suche in Google Scholar
  • 23 Baronti F, Mouradian MM, Davis TL, Giuffra M, Brughitta G, Conant KE, Chase TN. Continuous lisuride effects on central dopaminergic mechanism in Parkinson’s disease. Ann Neurol 1992; 32: 776-81.
    CrossrefPubMedSuche in Google Scholar
  • 24 Brefel C, Thalamus C, Rayet S, Lopez-Gil A, Fitzpatrick K, Bullman S, Citerone DR, Taylor AC, Monastruc JL, Rascol O. Effect of food on the pharmacokinetics of ropinirole in parkinsonian patients. Br J Clin Pharmacol 1998; 45: 412-5.
    CrossrefPubMedSuche in Google Scholar
  • 25 Christians U, Schmidt G, Bader A, Lampen A, Schottmann R, Linck A, Sewing KF. Identification of drugs inhibiting the in vitro metabolism of tacrolismus by human liver microsomes. Br J Clin Pharmacol 1996; 41: 187-90.
    CrossrefPubMedSuche in Google Scholar
  • 26 Alegre M, Noe E, Martinez JMLage. Psychosis due to the interaction of erythromycin and bromocriptine in Parkinson disease (Letter). Neurologia 1997; 12: 429.
    PubMedSuche in Google Scholar
  • 27 Thalamas C, Taylor A, Brefel-Courbon C, Eagle S, Fitzpatrick K, Rascol O. Lack of pharmacokinetic interaction between ropinirole and theophylline in patients with Parkinsons’s disease. Eur J Clin Pharmacol 1999; 55: 299-303.
    CrossrefPubMedSuche in Google Scholar
  • 28 Brecht HM. Dopaminagonisten im Vergleich. Aktuelle Neurologie 1998; 25: S310-16.
    Thieme ConnectSuche in Google Scholar
  • 29 Taylor AC, Beerahee A, Citerone DR, Cyronak MJ, Leigh TJ, Fitzpatrick KL, Lopez-Gil A, Vakil SD, Burns E, Lenox G. Lack of a pharma-cokinetic interaction at steady state between ropinirole and L-dopa in patients with parkinson`s disease. Pharmacotherapy 1999; 19: 150-6.
    CrossrefPubMedSuche in Google Scholar
  • 30 Minea D, Varga I, Falup-Pecurariu C, de Mey C, Retzow A, Althaus M. Influence of the dopamine agonist alpha-dihydroergocryptine on the pharmacokinetics of levodopa in patients with Parkinson´s disease. Clin Neuropharmacol 2001; 24: 235-8.
    CrossrefPubMedSuche in Google Scholar
  • 31 Nicholson G, Pereira AC, Hall GM. Parkinson’s disease and anaesthesia. Br J Anaesth 2002; 89: 904-16.
    CrossrefPubMedSuche in Google Scholar
  • 32 Reichmann H. Selegiline (L-Deprenyl). Aktuelle Neurologie 1998; 25: 322-3.
    Thieme ConnectSuche in Google Scholar
  • 33 Dingemanse J, Kneer J, Wallnofer A, Kettler R, Zurcher G, Koulu M, Korn A. Pharmacokinetic-pharmacodynamic interactions between two selective monoamine oxidase inhibitors: moclobemide and selegiline. Clin Neuropharmacol 1996; 19: 399-414.
    CrossrefPubMedSuche in Google Scholar
  • 34 Lyytinen J, Kaakkola S, Ahtila S, Tuomainen P, Teravainen H. Simultaneous MAO-B and COMT inhibition in L-Dopa-treated patients with Parkinson`s disease. Mov Disord 1997; 12: 497-505.
    CrossrefPubMedSuche in Google Scholar
  • 35 Lefebvre H, Noblet C, Moore N, Wolf LM. Pseudo-phaeochromocytoma after multiple drug interactions involving the selective monoamine oxidase inhibitor selegiline. Clin Endocrinol 1995; 42: 95-9.
    CrossrefPubMedSuche in Google Scholar
  • 36 Heikkinen H, Nutt JG, LeWitt PA, Kollar WC, Gordin A. The effects of different repeated doses of entacapone on the pharmacokinetics of L-Dopa and on the clinical response to LDopa in Parkinson`s disease. Clin Neuropharmacol 2001; 24: 150-7.
    CrossrefPubMedSuche in Google Scholar
  • 37 Illi A, Sundberg S, Ojala PKarlsson, Scheinin M, Gordin A. Simultaneous inhibition of catecholamine-O-methylation by entacapone and neuronal uptake by imipramine: lack of interactions. Eur J Clin Pharmacol 1996; 51: 273-6.
    CrossrefPubMedSuche in Google Scholar
  • 38 Renfrew C, Dickson R, Schwab C. Severe hypertension following ephedrine administration in a patient receiving entacapone. Anesthesiology 2000; 93: 1562.
    PubMedSuche in Google Scholar
  • 39 Jorga KM, Potteler B, Modi M, Rabbia M. Effect of tolcapone on the haemodynamic effects and tolerability of desipramine. Eur Neurol 2000; 44: 94-103.
    CrossrefPubMedSuche in Google Scholar
  • 40 Dingemanse J, Meyerhoff C, Schadrack J. Effect of the catechol-O-methyltransferase inhibitor entacapone on the steady-state pharmacokinetics and pharmacodynamics of warfarin. Br J Clin Pharmacol 2002; 53: 485-91.
    CrossrefPubMedSuche in Google Scholar
  • 41 Bianchine JR, Sunyapridakul L. Interactions between levodopa and other drugs: Significance in treatment of Parkinson’s disease. Drugs 1973; 06: 364-88.
    CrossrefPubMedSuche in Google Scholar
  • 42 Verspohl EJ. In: Ammon HPT: Arzneimittelneben-und -wechselwirkungen 4. Auflage Stuttgart: Wissenschaftliche Verlagsgesellschaft; 2001: 503-24.
    Suche in Google Scholar
  • 43 ABDA-Datenbank, Grosse Deutsche Spezialitätentaxe. Lauer-Taxe plus. Pharma Daig + Lauer GmbH, Fürth, Fischer Software GmbH, Stuttgart..
  • 44 Beizer JL. Treatment options in parkisnon’s disease. American Pharmacy 1995; 01: 20-32.
    Suche in Google Scholar